APYX

Apyx MedicalB

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

28%

Probability

Target price

$5.25

+38.5% vs current

Most likely

Base case

47%

Probability

Target price

$4.10

+8.2% vs current

B-

Bear case

25%

Probability

Target price

$2.40

-36.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

Post-earnings tone is modestly constructive but still cautious. The primary company evidence improved on May 7, 2026 through the Q1 release and 10-Q, especially the guidance raise and narrower losses [#8-K-2026-05-07] [#10-Q-2026-05-07]. By May 9, 2026, shares were around $3.67 versus the May 7 anchor close of $3.56, suggesting limited positive follow-through rather than a decisive re-rating. Coverage remains thin, and a clear delayed analyst revision set was not confirmed in checked sources, so this remains a monitored small-cap medtech execution story rather than a fully validated post-earnings upgrade thesis.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventAYON power-liposuction label expansion remains the clearest discrete upside triggerHigh impact

The company said it submitted a 510(k) in October 2025 to expand AYON to include power liposuction and still anticipates clearance in the second quarter of 2026 [#10-K-2026-03-10] [#10-Q-2026-05-07]. A timely clearance would broaden the platform claim set and could support surgeon adoption; a delay would weaken one of the cleaner forward hooks in the thesis.

2026-06-30catalystQ1 raise shifts focus to proving the new FY2026 outlook is repeatableHigh impact

Apyx reported Q1 2026 revenue of $12.5 million, up 32.4% year over year, with Surgical Aesthetics up 36.1% to $10.7 million, gross margin improving to 63.5%, and FY2026 total revenue guidance raised to $59.0 million-$60.0 million from $57.5 million-$58.5 million [#8-K-2026-05-07] [#10-Q-2026-05-07]. The near-term test is whether AYON adoption, international demand, and expense control hold well enough to keep the raise credible rather than looking like a one-quarter step-up.

2026-12-31catalystFull-year execution must offset OEM runoff while preserving liquidityHigh impact

Management said March 31, 2026 cash was $31.1 million and that, based on AYON uptake, working-capital management, and cost controls, it believes the company can yield cash through 2027 [#8-K-2026-05-07]. That longer-duration view still depends on Surgical Aesthetics growth outpacing the expected OEM decline, while the 10-Q and 10-K continue to frame liquidity, financing availability, and debt obligations as real constraints [#10-Q-2026-05-07] [#10-K-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology